Screen Shot 2017-10-03 at 12.02.40 PM.png

Who We Are

Patients are at the beginning, middle, and heart of all we do.

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on central nervous system disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.

 

What We Believe

Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.

 

Where We’re Starting

Our initial work is focused on the development, registration, and marketing of the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist for the potential treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. To date, no H3-receptor antagonist/inverse agonist has been approved by the US Food & Drug Administration.

We believe there is tremendous potential for pitolisant to help patients in need, and we are both proud and excited to be a part of potentially bringing this new therapy to the United States.

 

Our Leadership

Our company is led by a passionate team of industry veterans with a proven track record of success in developing and commercializing novel treatments for patients.

 
Screen Shot 2017-09-29 at 12.03.03 PM.png

Harmony Biosciences Management Team

Bob Repella

CEO

Read More

 
 

John C. Jacobs

EVP & Chief Commercial Officer

Read More

Andrew Serafin

SVP Business Development & Corporate Strategy

Read More

Nancy Lauby

Vice President, Human Resources

Read More

Jeffrey M.
Dayno, M.D.

EVP & Chief Medical Officer

Read More

 

Board of Directors

 

Jeffrey Aronin

Read More

Martin Edwards

Read More

Wilbur H. Gantz

Read More

Antonio Gracias

Read More

 
 
 

JACK NIELSEN

Read More

Aaron Royston

Read More

Juan Sabater

Read More

Andreas Wicki

Read More

 
 

Investors

 
Paragon-v2.png
Untitled-15.png
Untitled-12.png
Untitled-1.png
 
 
Untitled-14.png
Untitled-13.png
Untitled-16.png
 

PRESS RELEASES

MAY 31, 2018

Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting

Read More
 

MAY 21, 2018

Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant

Expanded Access Program For Pitolisant Is Open

Read More
 

October 5, 2017

Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing

Read More

NewsBg.jpg